Geneva: The World Health Organisation (WHO) on Friday said it has suspended Gilead’s Remdesivir from its so-called prequalification list (an official list of medicines used as a benchmark for procurement by developing countries), after issuing guidance against its use in hospitalized COVID-19 patients, said media reports.
“Yes we have suspended it from the PQ (prequalification list),” Tarik Jasarevic said in an emailed response to Reuters, the reports added.
“The suspension is a signla to countries that WHO, in compliance with the treatment guidelines, does not recommend countries procure the drug for COVID.”
He added that the WHO was not aware that any international procurers were providing the drug to low-and middle-income countries, reports said.
Also Read: Govt Helpline Gives Emotional Support To Children Battling COVID
